Literature DB >> 11813049

[Drug prescription for hospitalized pediatric patients: how can the quality be evaluated?].

M M Meiners1, G Bergsten-Mendes.   

Abstract

BACKGROUND: Pediatric patients called "therapeutic orphans" are usually excluded from clinical trials for development of new drugs, which, sometimes, are used empirically. This study evaluates the prescriptions for pediatric inpatients, and proposes criteria for evaluation of the quality of the prescriptions.
METHODS: The hospital pharmacist determined the prevalence of drug prescription in five pediatric wards. One day collection of all prescriptions for pediatric inpatients was performed in March, April, May and June 1999, and the data were jointly analyzed. Six criteria were proposed for quality evaluation of the drug prescriptions. The drugs were classified according to the ATC classification index.
RESULTS: The prescriptions of a total of 322 patients were collected in the four collection days. The three most common diagnoses were: pneumonia 40.4%, meningitis and meningococcemia 6%, diarrhea and dehydration 6%. The three most prescribed therapeutic classes were: nervous system (N ) 109%, general antiinfectives for systemic use ( J ) 81.9% and respiratory system ( R ) 69,0%. The three most prescribed drugs were: metamizole 88.3%, fenoterol 30.7% and penicillin G 25.0%. The quality evaluation showed 1. an excessive use of the intravenous route, 2. appropriate dose schedule for drugs with narrow therapeutic index, 3. no therapeutic duplication, 4. prescription of unapproved and off-label drugs, 5. frequent potential adverse drug interactions, and 6. prescription of drugs not in the therapeutic formulary of the hospital.
CONCLUSION: Very simple measures can improve the quality of the health care of pediatric inpatients as inclusion of adequate drug presentations in the hospital formulary, and a careful evaluation of the need of the intravenous route. This study also shows the hospital pharmacists acting as part of the multidisciplinary health care team.

Entities:  

Mesh:

Year:  2001        PMID: 11813049     DOI: 10.1590/s0104-42302001000400036

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.209


  7 in total

1.  Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil.

Authors:  Djanilson Barbosa Santos; Antonio Clavenna; Maurizio Bonati; Helena Lutescia Luna Coelho
Journal:  Eur J Clin Pharmacol       Date:  2008-08-07       Impact factor: 2.953

2.  USE OF DRUGS IN CHILDREN AGED ZERO TO FIVE YEARS OLD IN TUBARÃO, SANTA CATARINA, BRAZIL.

Authors:  Hellen Karoline Maniero; Alexandre Alvares Martins; Angelita Cristine Melo; Leonardo Petrus da Silva Paz; Rosiane de Bona Schraiber; Dayani Galato
Journal:  Rev Paul Pediatr       Date:  2018-11-14

3.  Severe Potential Drug-Drug Interactions and the Increased Length of Stay of Children in Intensive Care Unit.

Authors:  Elisangela da Costa Lima; Barbara Dias Camarinha; Nathalia Cristina Ferreira Bezerra; Anderson Gonçalves Panisset; Raquel Belmino de Souza; Marcus Tolentino Silva; Luciane Cruz Lopes
Journal:  Front Pharmacol       Date:  2020-12-03       Impact factor: 5.810

4.  Profile of drug interactions in hospitalized children.

Authors:  Jacqueline Martinbiancho; Joice Zuckermann; Luciana Dos Santos; Mariane M Silva
Journal:  Pharm Pract (Granada)       Date:  2007-10

5.  [Challenges on off label medicine use].

Authors:  Marisa Lima Carvalho
Journal:  Rev Paul Pediatr       Date:  2015-10-17

6.  Evaluation of potential drug-drug interactions in a pediatric population.

Authors:  Berna Terzioğlu Bebitoğlu; Elif Oğuz; Çağatay Nuhoğlu; Ayşe Ela Kurtdan Dalkılıç; Pelin Çirtlik; Fatime Temel; Ajla Hodzic
Journal:  Turk Pediatri Ars       Date:  2020-03-09

7.  A study of harmful drug-drug interactions due to polypharmacy in hospitalized patients in Goa Medical College.

Authors:  Akshay Khandeparkar; Padmanabh V Rataboli
Journal:  Perspect Clin Res       Date:  2017 Oct-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.